Generic Medicine Info
Hypersensitivity, hypertension, preeclampsia. Pregnancy.
Special Precautions
Patient with sepsis, coronary artery disease (CAD), obliterative vascular disease. Use during the second stage of labour. Renal and hepatic impairment. Lactation. Monitoring Parameters Monitor blood pressure, CNS status, and vaginal bleeding.
Adverse Reactions
Significant: Hypertension, myocardial ischaemia, MI; ergotism, pleural fibrosis, retroperitoneal fibrosis (prolonged use). Cardiac disorders: Chest pain, bradycardia, tachycardia, palpitation, coronary arterial spasm. Ear and labyrinth disorders: Tinnitus. Gastrointestinal disorders: Nausea, vomiting, diarrhoea, abdominal pain. Immune system disorders: Anaphylaxis. Metabolism and nutrition disorders: Water intoxication. Musculoskeletal and connective tissue disorders: Leg cramps. Nervous system disorders: Dizziness, headache, dysgeusia, seizure. Psychiatric disorders: Hallucination. Renal and urinary disorders: Haematuria. Respiratory, thoracic and mediastinal disorders: Dyspnoea, nasal congestion. Skin and subcutaneous tissue disorders: Rash, diaphoresis. Vascular disorders: Vasoconstriction, vasospasm, thrombophlebitis., hypotension.
Drug Interactions
Increased risk of ergot toxicity with CYP3A4 inhibitors (e.g. erythromycin, clarithromycin, ritonavir, delavirdine, ketoconazole, itraconazole, voriconazole). Enhance vasoconstrictive effect with β-blockers. Diminished therapeutic effect with anaesthetics (e.g. halothane, methoxyflurane). Reduced therapeutic effect of glyceryl trinitrate and other antianginal medications.
CIMS Class
Drugs Acting on the Uterus
ATC Classification
G02AB01 - methylergometrine ; Belongs to the class of ergot alkaloids. Used to induce abortion or augment labour and to minimize blood loss from the placental site.
Disclaimer: This information is independently developed by CIMS based on methylergometrine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in